- Home
- SKYE vs TEAF Comparison
SKYE vs TEAF Comparison
Compare SKYE & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- TEAF
- Stock Information
- Founded
- SKYE 2012
- TEAF 2017
- Country
- SKYE United States
- TEAF United States
- Employees
- SKYE N/A
- TEAF N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- SKYE Health Care
- TEAF Finance
- Exchange
- SKYE Nasdaq
- TEAF Nasdaq
- Market Cap
- SKYE 121.8M
- TEAF 158.9M
- IPO Year
- SKYE N/A
- TEAF N/A
- Fundamental
- Price
- SKYE $1.51
- TEAF N/A
- Analyst Decision
- SKYE Strong Buy
- TEAF
- Analyst Count
- SKYE 5
- TEAF 0
- Target Price
- SKYE $14.75
- TEAF N/A
- AVG Volume (30 Days)
- SKYE 1.7M
- TEAF 56.1K
- Earning Date
- SKYE 11-06-2025
- TEAF 01-01-0001
- Dividend Yield
- SKYE N/A
- TEAF 9.20%
- EPS Growth
- SKYE N/A
- TEAF N/A
- EPS
- SKYE N/A
- TEAF N/A
- Revenue
- SKYE N/A
- TEAF N/A
- Revenue This Year
- SKYE N/A
- TEAF N/A
- Revenue Next Year
- SKYE N/A
- TEAF N/A
- P/E Ratio
- SKYE N/A
- TEAF N/A
- Revenue Growth
- SKYE N/A
- TEAF N/A
- 52 Week Low
- SKYE $1.14
- TEAF $11.11
- 52 Week High
- SKYE $5.96
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- SKYE 28.46
- TEAF 54.08
- Support Level
- SKYE $1.78
- TEAF $11.58
- Resistance Level
- SKYE $1.76
- TEAF $12.03
- Average True Range (ATR)
- SKYE 0.32
- TEAF 0.11
- MACD
- SKYE -0.28
- TEAF 0.03
- Stochastic Oscillator
- SKYE 0.40
- TEAF 84.44
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Sustainable and Social Impact Term Fund Formerly Tortoise Essential Assets Income Term is a USA-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.